FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
The FDA approved labeling updates for the OTC weight loss medication alli (orlistat) 60 mg capsules to include warnings regarding the risk of acute kidney injury and kidney stones. The new label instructs consumers to consult a healthcare provider before use.
This affects the manufacturer of alli (orlistat 60 mg), regulatory professionals responsible for OTC labeling compliance, and pharmacovigilance teams monitoring adverse events related to weight loss medications.
The inclusion of acute kidney injury—though characterized as rare—indicates a significant safety signal that necessitates consumer-facing warnings. This regulatory action suggests that the FDA is prioritizing the transparency of renal risks for OTC products that may be used long-term without direct medical supervision. Professional interpretation suggests companies with similar active ingredients or therapeutic classes may need to review their own safety data for similar renal signals.
Regulatory and labeling teams should ensure that all current product inventory and marketing materials for Orlistat 60 mg reflect the updated 'Drug Facts' warnings. Pharmacovigilance departments should monitor post-market reports for acute kidney injury or nephrolithiasis to support future safety profile assessments.
The FDA has approved changes to the Drugs Facts Label of the over-the-counter (OTC) weight loss drug, alli (orlistat) 60 mg capsules, to warn of risks of acute kidney injury, which is a rare side effect of the medication. The labeling now advises consumers to ask a health care provider before using
Open in openFDA / FDA.gov